Use of Photobiomodulation and Mesenchymal Stem Cells in Polycystic Ovary Syndrome‐Induced Rats

Abstract

Evaluation was made of glycemia and gonadosomatic index (GSI) variations in rats with induced polycystic ovary syndrome (PCOS), following application of photobiomodulation (PBM) and injection of mesenchymal stem cells (MSCs). Eighty adult Wistar rats (n = 10 per group) were divided into control (C), PCOS, PBM, MSC, PCOS/PBM, PCOS/MSC, PBM/MSC, and PCOS/PBM/MSC groups. PCOS was induced by single injection of estradiol valerate (EV) (2 mg/kg/bw/i.m.). The animals were evaluated 30 and 60 days after induction. MSCs were injected directly into the ovaries (5×105cells/0.2 mL physiological solution in each ovary), on the same day as PCOS induction. The animals were irradiated with a laser (wavelength 808 nm, power 60 mW), using a dose of 3 Joules(J)/point on each ovary, 3 times weekly, totaling 6 J of energy for each irradiated animal per day of application. After sacrifice, plasma glucose was determined and the ovaries were removed and weighed for GSI determination (ovary weight/body weight × 100). Statistical analysis of the data was performed using ANOVA and Fisher's test. The results were reported as means ± SEM. This study was approved by the local Animal Care and Use Committee (CEUA–UNIARA, protocol nº 019/16). Glycemia: There were reductions in glycemia for all exposed groups, compared to the 30‐day C group (260.2 ±37 mg/dL), with the lowest values for the PCOS/PBM/MSC group (103.6 ±12.58 mg/dL). Compared to the 30‐day PCOS group (186.2 ±79.7 mg/dL), glycemia was lower for groups PBM/MSC (115.6 ±15.32 mg/dL) and PCOS/PBM/MSC (103. 6 ±12.58 mg/dL). After 60 days of treatment, the PCOS/MSC group presented lower glycemia (101.8 ±20.03 mg/dL), compared to the C group (160.6 ±42.3 mg/dL). 30‐days GSI: The PCOS/PBM(0.019 ±0.006%), PCOS/MSC (0.018 ±0.0061%), PBM/MSC (0.029 ±0.02%), and PCOS/PBM/MSC (0.027 ±0.008%) groups showed increased GSI, compared to the C group (0.012 ±0.0013%). 60‐daysGSI: There were increases of GSI for the PCOS/MSC (0.013 ±0.0048%), PBM/MSC (0.02 ±0.0035%), and PCOS/PBM/MSC (0.017 ±0.0036%) groups, compared to the C group (0.008 ±0.0039%). The results indicated that the PBM/MSC combination reduced glycemia 30 days after PCOS induction by EV. In addition, the combined use of PBMand MSC resulted in higher GSI, 30 days after PCOS induction, compared to the PCOS group, which was indicative of ovarian modulations induced by this treatment. Morphological, immunohistochemical, and hormonal studies are underway in our laboratory to complement the present study.Support or Funding InformationFunding: FAPESP (Grant 2016/02811‐4)This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.